Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone650-574-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.45 billion
Profitability
Miscellaneous
Employees11,000
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable
Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences announced a quarterly dividend on Tuesday, February 4th. Investors of record on Friday, March 13th will be given a dividend of $0.68 per share on Monday, March 30th. This represents a $2.72 annualized dividend and a yield of 3.90%. The ex-dividend date of this dividend is Thursday, March 12th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.63. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Tuesday, February, 4th. The biopharmaceutical company reported $1.30 EPS for the quarter, missing the Zacks' consensus estimate of $1.67 by $0.37. The biopharmaceutical company had revenue of $5.88 billion for the quarter, compared to analyst estimates of $5.74 billion. Gilead Sciences had a return on equity of 35.49% and a net margin of 23.99%. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS. View Gilead Sciences' Earnings History.
When is Gilead Sciences' next earnings date?
What guidance has Gilead Sciences issued on next quarter's earnings?
Gilead Sciences updated its FY20 earnings guidance on Tuesday, February, 4th. The company provided earnings per share (EPS) guidance of 6.00-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.02. The company issued revenue guidance of 21.8-22.2 billion, compared to the consensus revenue estimate of $22.54 billion.
What price target have analysts set for GILD?
24 analysts have issued 1-year price objectives for Gilead Sciences' shares. Their forecasts range from $60.00 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $77.96 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View Analyst Price Targets for Gilead Sciences.
What is the consensus analysts' recommendation for Gilead Sciences?
24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 2 sell ratings, 9 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gilead Sciences.
What are Wall Street analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. Needham & Company LLC analysts commented, "Gilead reported $5.28B in 1Q19 total revenue, in line w/ our $5.27B and consensus $5.3B ests. Product sales were $5.20B (-8% q/q), matching our $5.16B and consensus $5.2B ests. Mgmt had guided for 12-14% sequential decline. All annual guidance unch. Non-GAAP EPS $1.76 was above our $1.64 and consensus $1.61 ests. New CEO O’Day outlined priorities (Strengthen pipeline [internal and external business development]; Ensure optimal commercial delivery; and Reassess organizational structure [‘evolution not revolution’]) and announced that Kite will operate as a separate business unit w/ a new CEO reporting directly to O’Day. Filgotinib MAA to be submitted 3Q19, but no update yet on strategy/ timing for NDA submission. NASH ATLAS drug combination trial results expected 4Q19 (unch). HOLD." (5/6/2019)
- 2. Cowen Inc analysts commented, "NTLA reported 1Q results of $10.4M in collaboration revenue, $34M in -$0.49 vs consensus EPS of -$0.57. 1Q cash balance was $296.6M, which management estimates will fund operations into 1H 2021. The call included several updates on the pipeline in in-vivo editing and ex-vivo engineered T-Cells: 1) NTLA remains on track for NDA submission of NTLA-2001 for ATTR in 2020 and preparations (manufacturing & toxicology) are ongoing. 2) Data presented at ASGCT was the first demonstration of CRISPR/Cas9-based targeted insertion in the liver of non-human primates. We view this as a validation of NTLA’s modular LNP+AAV approach to in-vivo editing. 3) ASGCT presentation on engineered cell therapy (WT1 insertion into >95% of isolated T-cells) shows progress in cell therapy." (5/3/2019)
- 3. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past three months." (5/2/2019)
- 4. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy." (4/25/2019)
- 5. Mizuho analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (4/22/2019)
Has Gilead Sciences been receiving favorable news coverage?
Press coverage about GILD stock has trended positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Gilead Sciences earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Gilead Sciences.
Are investors shorting Gilead Sciences?
Gilead Sciences saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 17,780,000 shares, a decrease of 16.5% from the January 15th total of 21,300,000 shares. Based on an average trading volume of 7,270,000 shares, the short-interest ratio is presently 2.4 days. Approximately 1.4% of the shares of the company are short sold. View Gilead Sciences' Current Options Chain.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).
What other stocks do shareholders of Gilead Sciences own?
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
- Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
- Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
- Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
- Mr. Daniel O'Day, Chairman & CEO (Age 55)
Who are Gilead Sciences' major shareholders?
Gilead Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (6.73%), State Street Corp (4.59%), Bank of New York Mellon Corp (2.30%), Capital World Investors (1.64%), Geode Capital Management LLC (1.52%) and Renaissance Technologies LLC (1.34%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Gayle E Wilson, Gregg H Alton, John C Martin, John Francis Cogan, Olsen Per Wold, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Which major investors are selling Gilead Sciences stock?
GILD stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., FMR LLC, Alliancebernstein L.P., Franklin Resources Inc., First Trust Advisors LP, Prudential Financial Inc., Marshall Wace LLP and Man Group plc. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Gayle E Wilson, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences.
Which major investors are buying Gilead Sciences stock?
GILD stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Valueworks LLC, AQR Capital Management LLC, Renaissance Technologies LLC, Janus Henderson Group PLC, AJO LP, Bank of New York Mellon Corp and Schroder Investment Management Group. View Insider Buying and Selling for Gilead Sciences.
How do I buy shares of Gilead Sciences?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of GILD stock can currently be purchased for approximately $69.70.
How big of a company is Gilead Sciences?
Gilead Sciences has a market capitalization of $88.18 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe.View Additional Information About Gilead Sciences.
What is Gilead Sciences' official website?
How can I contact Gilead Sciences?
Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]
MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
